Loading
Carbamazepine · Regulatory label update
U.S. Food and Drug Administration · July 15, 2026
An action by a regulator. Authoritative on labelling and availability.
This is a U.S. FDA supplemental approval granting a labeling change to Tegretol (carbamazepine 200 mg tablet) submitted by Novartis on 15 July 2026. The record does not contain clinical trial results, efficacy data, or safety findings; it documents only the regulatory approval of the labeling modification itself.
Regulatory label update. United States (FDA).
This is a U.S. FDA supplemental approval granting a labeling change to Tegretol (carbamazepine 200 mg tablet) submitted by Novartis on 15 July 2026. The record does not contain clinical trial results, efficacy data, or safety findings; it documents only the regulatory approval of the labeling modification itself.
This record does not contain clinical trial results, efficacy data, or safety evidence.
Clinicians should refer to the updated Tegretol product labeling for revised prescribing information, warnings, or indications. This record does not convey the specific content of the labeling change or its clinical rationale.
FDA supplemental approval for labeling change to Tegretol (carbamazepine); does not contain clinical trial data or efficacy evidence.
As stated by the source record.
Clinicians should refer to the updated Tegretol product labeling for revised prescribing information, warnings, or indications. This record does not convey the specific content of the labeling change or its clinical rationale.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application NDA016608. This is a regulatory action record, not a clinical study. Brand name: TEGRETOL. Active ingredient: CARBAMAZEPINE. Sponsor: NOVARTIS. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-15. Products: TEGRETOL, TABLET, ORAL, CARBAMAZEPINE 200MG.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.